Stryker marked a -0.7% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $288.85? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Stryker Corporation operates as a medical technology company.
-
Stryker belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
-
The company's P/B ratio is 6.13
-
Stryker has a trailing 12 month Price to Earnings (P/E) ratio of 42.8 based on its trailing 12 month price to earnings (EPS) of $6.75 per share
-
Its forward P/E ratio is 25.0, based on its forward earnings per share (EPS) of $11.55
-
SYK has a Price to Earnings Growth (PEG) ratio of 2.64, which shows the company is overvalued when we factor growth into the price to earnings calculus.
-
Over the last four years, Stryker has averaged free cash flows of $2.29 Billion, which on average grew 3.9%
-
SYK's gross profit margins have averaged 64.0 % over the last four years and during this time they had a growth rate of -0.7 % and a coefficient of variability of 2.8 %.
-
Stryker has moved 23.0% over the last year compared to 17.0% for the S&P 500 -- a difference of 6.0%
-
SYK has an average analyst rating of buy and is -9.73% away from its mean target price of $320.0 per share